| Applications: | Immunodepletion/Immunocompetition |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | SOCS1 Blocking Peptide for STJ503079 is synthetically produced from the 170-212 sequence and is suitable for use in western blot applications. |
| Formulation: | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Dilution Range: | WB: IHC: 1:100 |
| Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: | 170-212 |
| Specificity: | This blocking peptide is recommended for use in combination with SOCS1 antibody, STJ503079 |
| Immunogen: | Synthetic peptide taken within amino acid region 170-212 on human Suppressor of Cytokine signaling 1 protein. |
| Background | SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein-tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. |
Information sourced from Uniprot.org